Key Developments: Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

152.49USD
4:00pm EDT
Price Change (% chg)

$-2.21 (-1.43%)
Prev Close
$154.70
Open
$150.17
Day's High
$154.35
Day's Low
$147.53
Volume
326,285
Avg. Vol
278,042
52-wk High
$176.58
52-wk Low
$70.33

Search Stocks

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals PLC's subsidiary to acquire rights to Defibrotide In Americas From Sigma-Tau Pharmaceuticals, Inc.
Wednesday, 2 Jul 2014 08:00am EDT 

Jazz Pharmaceuticals PLC:Signs definitive agreement with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) under which subsidiary of Jazz Pharmaceuticals plc (Jazz) will acquire from Sigma-Tau rights to defibrotide in United States (U.S.) and all other countries in the Americas.Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year.Sigma-Tau would receive an upfront payment of $75 mln upon closing of the transaction.Sigma-Tau would be eligible to receive milestone payments of $25 mln upon the acceptance for filing by FDA of first NDA for defibrotide for VOD and up to an additional $150 mln based on the timing of potential FDA approval of defibrotide for VOD.  Full Article

Jazz Pharmaceuticals PLC reaffirms FY 2014 guidance
Thursday, 8 May 2014 04:10pm EDT 

Jazz Pharmaceuticals PLC:Continues to expect FY 2014 revenues of $1.100-$1.160 bln.FY 2014 GAAP net income per diluted share of $1.81-$2.30.FY 2014 Non-GAAP Adjusted Net Income Per Diluted Share of $8.00-$8.25.FY 2014 revenue of $1.135 bln and EPS of $8.20 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC announces management change
Tuesday, 25 Feb 2014 04:10pm EST 

Jazz Pharmaceuticals PLC:Says that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests.Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period.Matthew Young, senior vice president of corporate development at Jazz Pharmaceuticals, has been appointed senior vice president and CFO, reporting to Bruce Cozadd, chairman and chief executive officer, as of the effectiveness of Falberg's resignation.Young joined Jazz Pharmaceuticals in early 2013.  Full Article

Jazz Pharmaceuticals PLC gives FY 2014 guidance in line with analysts' estimates
Tuesday, 25 Feb 2014 04:05pm EST 

Jazz Pharmaceuticals PLC:Expects fiscal 2014 revenues of $1.100-$1.160 bln.Expects fiscal 2014 GAAP net income per diluted share of $2.31-$2.84.Expects fiscal 2014 non-GAAP adjusted net income per diluted share of $8.00-$8.25.Fiscal 2014 revenue of $1.084 bln and EPS of $8.07 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC's subsidiary completes tender offer for Gentium S.p.A. shares
Friday, 21 Feb 2014 08:00am EST 

Jazz Pharmaceuticals PLC:Says subsequent offering period of the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares of Gentium S.p.A. for $57. per share.Says tender offer is complete.Says tender agent for the tender offer has advised Jazz Pharmaceuticals that, as of the expiration of the tender offer, a total of 17,427,624 Gentium ordinary shares and ADSs were properly tendered and not withdrawn.Says these ordinary shares and ADSs represent about 98 percent of Gentium's issued and outstanding, and fully diluted, ordinary shares and ADSs.  Full Article

Jazz Pharmaceuticals PLC gives FY 2013 revenue guidance above analysts' estimates - Conference call
Monday, 13 Jan 2014 01:00pm EST 

Jazz Pharmaceuticals PLC:Says that based on the guidance it gave in Nov. 2013, the company is targeting 50% revenue growth in fiscal 2013 over fiscal 2012.Reported revenue of $585.98 mln in fiscal 2012.Revenue of $874.41 mln for fiscal 2013 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC's Subsidiary and Gentium SpA announce agreement for Jazz Pharmaceuticals to acquire Gentium for $57.00 per share
Thursday, 19 Dec 2013 04:43pm EST 

Jazz Pharmaceuticals PLC and Gentium SpA:Says they have entered into a definitive agreement pursuant to which a subsidiary of Jazz Pharmaceuticals will make a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares, in a transaction that is valued at about $1 billion.Says the transaction is expected to close in the first quarter of 2014.Says it expects to finance the transaction with a combination of cash on hand, the proceeds from an incremental term loan and revolver borrowings under its existing senior secured credit facility.Says Barclays has provided a binding commitment letter for a $500 million incremental term loan.Says its financial advisor for the transaction is Barclays, and its primary legal advisors are Weil, Gotshal & Manges LLP, Baker & McKenzie, Cooley LLP, Hogan Lovells and Gattai, Minoli & Partners.Says Gentium's financial advisor for the transaction is Jefferies LLC, and its primary legal advisors are Skadden Arps Slate Meagher & Flom and Gianni, Origoni, Grippo & Capelli Partners.  Full Article

Jazz Pharmaceuticals PLC Narrows FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Raises Low End Of Prior FY 2013 EPS Guidance To A Range In Line With Analysts' Estimates
Tuesday, 5 Nov 2013 04:05pm EST 

Jazz Pharmaceuticals PLC announced that for fiscal 2013, it expects revenue to be in the range of $867-$877 million, GAAP net income per diluted share in the range of $3.63-$3.79 and adjusted net income per diluted share $6.30-$6.40. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $872 million and EPS of $6.30 for fiscal 2013.  Full Article

Jazz Pharmaceuticals PLC Raises FY 2013 Guidance
Tuesday, 6 Aug 2013 04:05pm EDT 

Jazz Pharmaceuticals PLC announced that for fiscal 2013, it expects revenues guidance to be in the range of $860-$880 million and adjusted net income per diluted share (EPS) of $6.20 to $6.40. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $853 million and EPS of $6.21 for fiscal 2013.  Full Article

Jazz Pharmaceuticals PLC Reaffirms FY 2013 Guidance-Conference Call
Tuesday, 21 May 2013 09:30am EDT 

Jazz Pharmaceuticals PLC announced that for fiscal 2013, it expects revenues guidance to be in the range of $830 million up to $860 million and adjusted EPS guidance of $6.10 to $6.30. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $849 and EPS of $6.15 for fiscal 2013  Full Article

BUZZ-Jazz Pharmaceuticals Plc: Acquires rights to liver drug

** Acquires U.S. marketing rights for liver drug defibrotide in the U.S. from privately held Sigma Tau Pharmaceuticals Inc for $75 million

Search Stocks